On May 14, 2018 Augmenix, Inc. reported that they will be exhibiting at this year’s American Urological Association meeting in San Francisco, California (Press release, Augmenix, MAY 14, 2018, View Source [SID1234526598]). Located at Booth 6251 Hall D, the company will be featuring their leading product, SpaceOAR hydrogel, which is used in patients receiving radiation therapy for prostate cancer. Attendees of the AUA meeting are invited to visit the exhibit to learn about the latest developments that make SpaceOAR hydrogel the #1 rectal spacer for prostate cancer radiotherapy worldwide.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Highlights Include:
In booth presentations from Urology experts including Dr. Katsuto Shinohara, from University of California, San Francisco who will speak about the clinical benefits and procedural overview of SpaceOAR hydrogel. Dr. Evan Goldfischer from the Premier Medical Group and Clinical Assistant Professor of Urology at the New York Medical College will speak about integrating SpaceOAR hydrogel into office-based Urology practices. Mark Painter, CEO of PRS, LLC will present the recent positive developments in national reimbursement for the SpaceOAR hydrogel procedure.
Augmenix will also unveil its new customized hands-on simulators at the exhibit, designed to provide Urologists with the ability to perform the SpaceOAR procedure before using it with patients.
The company will also formally launch the Augmenix Spacing Academy, designed to provide the information, tools and on-site support to enable Urologists to experience consistent and optimal patient outcomes.
About SpaceOAR Hydrogel
In April 2015, the Food and Drug Administration (FDA) cleared SpaceOAR hydrogel. In a prospective, randomized, multi-center clinical trial in the United States, patients treated with SpaceOAR hydrogel prior to prostate cancer radiation treatment demonstrated bowel, urinary, and sexual benefits through three years median of follow-up. The study found that the patients who did not receive SpaceOAR hydrogel experienced a clinically significant decline in bowel, urinary, and sexual quality of life eight times more often than patients who received SpaceOAR hydrogel. (1,2)
Most recently, Augmenix announced that a Category 1 CPT code (55874) was issued for SpaceOAR hydrogel, which became effective on January 1, 2018. SpaceOAR hydrogel is covered by six out of seven Medicare Administrative Contractors (MACs), Geisinger Health Plan, Aetna, Inc., and military payer TRICARE.